abstract: One of the non-classical human leukocyte antigen (HLA) class Ib proteins, HLA-G, is believed to exert important immunoregulatory functions, especially during pregnancy. The presence of HLA protein in paternal seminal fluid has been suggested to have an influence on the risk of developing pre-eclampsia. We have investigated whether HLA-G protein is present in human seminal plasma and in different tissue samples of the male reproductive system. Western blot technique and a soluble HLA-G (sHLA-G) assay were used to detect sHLA-G in human seminal plasma samples. Immunohistochemical staining was performed on paraffin-embedded tissue samples. We detected sHLA-G protein in seminal plasma, and HLA-G expression in normal testis and in epididymal tissue of the male reproductive system but not in the seminal vesicle. Furthermore, the results indicated a weak expression of HLA-G in hyperplastic prostatic tissue. In summary, several of the findings reported in this study suggest an immunoregulatory role of HLA-G in the male reproductive system and in seminal plasma.
Introduction
The non-classical human leukocyte antigen (HLA) class Ib molecule, HLA-G, has a restricted pattern of expression but is expressed at the feto-maternal interface, especially on extravillous cytotrophoblasts and amnion epithelial cells. HLA-G seems to be an integral part of placental development as an inducer of immunological tolerance, allowing the implantation of the semi-allogenic embryo into the maternal tissues. HLA-G is expressed both as membrane bound (HLA-G1, -G2, -G3 and -G4) and soluble isoforms (HLA-G5, -G6 and -G7). Furthermore, HLA-G molecules can be shed or proteolytically cleaved from the cell surface, so-called soluble HLA-G1 (sHLA-G1) and sHLA-G2, which correspond to the soluble HLA-G5 and HLA-G6 isoforms, respectively. Soluble HLA-G5 and -G6 are generated by the retaining of intron 4, which includes a stop codon, in the HLA-G transcript (Kovats et al., 1990; Hviid et al., 1998; Hunt et al., 2005; Hviid, 2006; Carosella et al., 2008) .
Only a few studies have focused on HLA-G expression in the male reproductive system (Ryan et al., 2002; Langat et al., 2006) . For at least two reasons, it can be hypothesized that HLA-G might be present in male reproductive tissues. First, HLA-G has been detected in immuneprivileged sites such as the placenta and the eye (e.g. Le Discorde et al., 2003) . In this regard, the testis is also considered an immuneprivileged site. Secondly, seminal plasma seems to have an immunological 'priming' effect in the female before implantation of the embryo (Robertson, 2005) .
Pre-eclampsia is a multisystem disorder that usually develops in the second or third trimester of pregnancy, and can have fatal consequences. The involvement of some kind of immune maladaption is one of the main hypotheses of the etiology of pre-eclampsia. Polymorphisms in the HLA-G gene have been associated with the risk of developing pre-eclampsia (Hylenius et al., 2004; Moreau et al., 2008) . Furthermore, previous studies have shown that sperm, and probably HLA in the seminal fluid, in some way might have an influence on the incidence of pre-eclampsia (Koelman et al., 2000; Robertson et al., 2003; Saito et al., 2007) . Therefore, it can be hypothesized that paternal sHLA molecules, perhaps including HLA -G, in the seminal plasma, may be involved in inducing tolerance in the mother to paternal antigens. This induction of allogeneic tolerance to paternal HLA molecules of the fetus may be important for the success of the pregnancy.
A few studies on HLA class Ib gene expression in male gametogenic cells (Fiszer et al., 1997) and on immature and mature human germ cells (Hutter and Dohr, 1998) have been reported. However, the only studies performed so far within male reproductive systems, in which the focus of the investigation being HLA-G, or a HLA-G homolog gene, has been in the rhesus monkey (Ryan et al., 2002) , and in human male prostate (Langat et al., 2006) . Ryan et al. (2002) investigated the expression of the non-classical major histocompatibility complex class I molecule Mamu-AG (a homolog gene to human HLA-G) in different anatomical sites in male rhesus monkeys. Ryan et al. (2002) detected Mamu-AG-5 mRNA coding for soluble Mamu-AG in rhesus testis (Ryan et al., 2002) . A monoclonal antibody (mAb) against membrane-bound Mamu-AG stained a few cells in the testis. Also, it was found that Sertoli cells, spermatocytes and spermatids were consistently positive for immunostaining with 16G1, which is a mAb against the retained intron 4 in soluble HLA-G5. Finally, the presence of Mamu-AG-5 in the syncytiotrophoblasts of the chorionic villi of the rhesus placenta was observed. By RT-PCR, Langat et al. (2006) found mRNAs specific for HLA-G1, -G2, -G5 and -G6 in samples of normal prostate gland and prostate adenocarcinomas. Furthermore, by using immunohistochemical staining they observed that out of the four HLA-G mRNA isotypes, only HLA-G5 protein was present in the prostate and prostatic secretions. Prostatic adenocarcinoma tumor cells showed almost an absence of the HLA-G5 protein, although the protein remained detectable in the secretions (Langat et al., 2006) .
The aim of this present study was to investigate whether there are any sHLA-G in seminal plasma (defined as the liquid supernatant after centrifugation of semen) and/or in semen (seminal fluid containing spermatozoa). Furthermore, the aim was also to investigate whether HLA-G is present in tissue samples from testis, prostate, epididymis, ductus deferens and seminal vesicles of the male reproductive system. The presence of HLA-G in the male reproductive system and in semen could play a role in induction of immunological tolerance in the fertile female to paternal antigens and thereby for the success of pregnancy.
Materials and Methods

Antibodies
The monoclonal HLA-G antibodies MEM-G/1, MEM-G/2, 2A12 and 5A6G7 were used to detect HLA-G. All mAbs were obtained from Exbio Praha (Prague, Czech Republic). MEM-G/1 and MEM-G/2 are mouse monoclonal [immunoglobulin G1 (IgG1) ] antibodies that recognize the free heavy chains of all the HLA-G isoforms by western blot and paraffin-embedded immunohistochemistry. The 2A12 and 5A6G7 mAbs (mouse IgG1) are antibodies raised against the intron 4-retaining protein sequence of sHLA-G. Thus, these two antibodies are developed to discriminate between sHLA-G protein yielded by shedding from membranebound HLA-G isoforms that do not contain the intron 4-encoded protein sequence and the recognition of soluble HLA-G5/HLA-G6 produced from the intron 4-retaining alternatively spliced mRNAs. All the mAbs used in the study are listed in Table I .
Samples and tissues
The following different tissue samples were included in the immunohistochemical analyses: endometrium from abortion tissue (6th week of gestation; one sample), normal placenta (39th week of gestation; one sample), normal testis (three samples), testis with atrophy (one sample), prostate with hyperplasia (seven samples), normal epididymis (five samples), normal ductus deferens (four samples) and normal seminal vesicle (four samples).
Preparation of seminal samples for immunohistochemistry
Seminal samples and separated sperm cells from four donors were immobilized in a coagulation gel and fixed in formalin before being paraffin-embedded for immunohistochemistry. The seminal samples were used directly or the sperm cells and other cells were separated by centrifugation. Centrifugation was performed at 1000g for 10 min at 48C followed by the removal of the seminal plasma. The seminal plasma was stored at 2208C until ELISA was performed. The cells from the seminal sample were used directly or washed two times by resuspending them in 2 ml of 0.9% NaCl followed by centrifugation steps at 800g for 10 min at 48C. Leukocytes from a normal human donor were used as a control. A sample of 100 ml blood diluted in 0.9% NaCl was lysed using 200 ml lysing buffer diluted in 1800 ml water. After 10 min, the leukocytes were washed two times by resuspending them in 1.5 ml 0.9% NaCl followed by centrifugation at 800g for 5 min at room temperature. Then, the cells were immobilized in a coagulation gel in the same way as for the raw seminal samples. Three drops of human plasma were added along with two drops of bovine thrombin. After 1 min, a coagulation gel complex had formed and this was fixed over night in 1 ml formalin. For the raw seminal samples a double volume of plasma and thrombin was added.
Immunohistochemistry
Immunohistochemical studies were performed on paraffin-embedded sections using mAbs specific for HLA-G (MEM-G/1, MEM-G/2, 2A12, 5A6G7; Exbio Praha, Czech Republic) and negative control antibodies PPV-06 (mouse Ig-isotype matched mAb against a plant pathogen; Exbio Praha), and MOPC-21 (mouse Ig-isotype matched mAb; Exbio Praha). Briefly, the sections were dewaxed in xylene before immunostaining and placed in 99% ethanol. Endogenous peroxidase activity was quenched with 0.5% H 2 O 2 in 99% ethanol for 20 min, after which sections were washed in tap water. For pretreatment with heat-induced epitope retrieval, the slides were placed in a 10.0 mM Tris and 0.5 mM EGTA buffer (pH 8.7 -8.8 ) and microwaved in a domestic microwave oven at the maximum power (900 W) for 10 min followed by heating for 20 min at the medium power (400 W). Slides were subsequently kept in buffer for 10 min to cool. After pretreatment, slides were washed in tap water, followed by washes in 0.05 M Tris-HCl wash buffer (pH 7.6) containing 0.05% Tween 20 (Dako, Glostrup, Denmark). The slides were incubated with primary antibodies (see Table I ) diluted in Power Block solution (BioGenex, San Ramon, CA, cat.no. HK085-5K) for 30 min at room temperature. The sections were then rinsed in the wash buffer (3 × 5 min), and the reactions were detected with Super Sensitive polymer-horseradish peroxidase (HRP) reagent (BioGenex, cat.no. QD410D-XCX) and viewed with 3,3-diaminobenzidine ImmPACT Substrate chromogen solution (Vector laboratories cat.no. SK-4105) following the manufacture's instructions. Finally, slides were rinsed in water and counterstained with Mayers hematoxylin. The sections were then examined microscopically.
A 22-mer peptide (sequence WSKEGDGGIMSVRESRSLSEDL) was synthesized for peptide absorbing control experiments (GenScript, NJ, USA) corresponding to the C-terminal amino acid sequence of the soluble HLA-G5 and -G6 proteins. Briefly, peptide was added to the antibody working solutions of HLA-G (MEM-G1, MEM-G/2, 2A12, 5A6G7) in a concentration that was 10× higher than the Ig-concentration. According to the data sheets, concentrations of the HLA-G antibodies were 1 mg/ml. The peptide-antibody solutions were pre-incubated for 30 min at room temperature, then applied to the sections and incubated following the procedure described earlier.
The paraffin-embedded raw seminal samples, isolated sperm cells and blood leukocytes, for immunohistochemistry were studied in the same way as described earlier for tissue sections. The following antibodies were tested: 5A6G7 (dilutions 1:50 and 1:500), MEM-G/1 (dilution 1:750), MEM-G/2 (dilution 1:2000), anti-CD45 (or leukocyte common antigen; dilution 1:50; clone X16/99, Novocastra) and isotype control PPV-06 (dilution 1:500).
The study was carried out in accordance with the ethical standards of the Helsinki Declaration and was approved by the Committee on Biomedical Research Ethics of the Zealand Region of Denmark.
Preparation of seminal plasma and normal sperm samples for western blotting
Normal semen was collected from male donors by masturbation. The semen was allowed to liquefy at room temperature for an hour and afterwards divided into 9 ml microfuge tubes (Nunc, Roskilde, Denmark). Seminal plasma was separated from the sperm by centrifuging at 1000g for 10 min at 48C and stored at 2208C until electrophoresis was performed. Each aliquot of sperm (precipitate) was then washed by suspension in 2 ml phosphate-buffered saline (PBS; pH 7.4) and then centrifuged at 800g for 10 min at 48C. The supernatant was discarded. The sperm aliquots were subsequently suspended in 300 ml of protease inhibitor cocktail buffer (Sigma, Missouri, USA) and stored at 2808C until use. As a negative control, semen from a boar (Hatting-KS, Denmark) was used; this was prepared in the same way as the human semen samples. Furthermore, human kidney tissue lysate (Abcam, Cambridge, UK) was used, also as a negative control. Human placenta whole cell lysate (Abcam, Cambridge, UK) was included as a positive control.
Sodium dodecyl sulfate -polyacrylamide gel electrophoresis and western blotting
Seminal plasma samples for western blots were diluted 1:2 by mixing 10 ml of seminal plasma with 10 ml sample buffer [sample buffer: Laemmli 2 × concentrate containing 4% sodium dodecyl sulfate (SDS), 20% glycerol, 10% 2-mercaptoethanol, 0.004% bromphenol blue and 0.125 M TrisHCl, pH 6.8 (Sigma-Aldrich, Steinheim, Germany)]. Afterwards samples were boiled for 5 min at 998C. Each gel was loaded with a standard protein of broad Prestain Molecular Weight Marker, 7.6 -195 kDa (Twocolor SDS Marker, PAGEgel, San Diego, USA). Afterwards, samples were loaded on a precast 12% gradient 12-well SDS polyacrylamide gel (PAGEgel). Proteins were then separated by electrophoresis and were transferred to nitrocellulose membranes (Pierce, Rockford, USA) using a Mini Trans-Blot Cell apparatus (Bio-Rad, Life Science Research, Denmark), according to the manufacture's instructions for blotting. The membranes were blocked at room temperature for 45 min in blocking buffer containing 5% skim milk powder (Merck, Darmstadt, Germany) dissolved in 1 × PBS. The membranes were washed with wash buffer containing 1 × PBS with 5% (bovine serum albumin/fraction V) and incubated over night at room temperature, with primary antibody MEM-G1 in a concentration of 10 mg/ml (recommended dilution by the antibody supplier, Exbio, Praha), diluted in wash buffer. The membranes were washed with the wash solution. Then, membranes were incubated for 2 h at room temperature with secondary polyclonal rabbit anti-mouse immunoglobulins conjugated with HRP (Dako) diluted 1:1000 in wash buffer. After the incubation with conjugate, membranes were again washed four times for 10 min in wash solution. After incubation, detection using LumiGLO Reserve Chemiluminescent Substrate kit (KPL, Gaithersburg, MD, USA) was carried out. Bands were viewed by the use of a LAS-4000 Luminescent Image Analyzer (Fujifilm Life Science, Stamford, CT, USA) for varying exposure times ranging from 10 s to 5 min to ascertain the most optimal pictures.
Soluble HLA-G ELISA
To quantify sHLA-G in seminal plasma, we used a commercially available ELISA kit (Exbio/BioVendor, Praha) that uses the mAb MEM-G/9 specific for sHLA-G1 and HLA-G5. Six diluted human seminal plasma samples from male donors were loaded manually into the wells and incubated for 20 h. The remaining procedure was programmed into and carried out using the automated analyzer BEP2000 (Dade Behring) according to the manufacture's instructions. As negative controls, both a blind and a sample with boar seminal plasma were used. All samples were tested in duplicates. Soluble HLA-G standard was diluted to obtain a calibrator curve within a range from 3.91 to 125 U/ml for sHLA-G ELISA. Results were adjusted for the sample dilution. The total protein concentration levels were quantified in the seminal plasma samples by using an ARCHI-TECT ci8200 Integrated System (Abbott Diagnostics). Afterwards, results from the ELISA were adjusted by dividing sHLA-G concentration (U/ml) with total protein concentration (mg/ml).
Results
The presence of HLA-G in different parts of the human male reproductive system Immunohistochemical analysis of HLA-G was performed in the tissues listed in Materials and Methods; all paraffin-embedded tissue slides. Representative immunohistochemical sections are presented in Figs 1 -5. As negative controls, the staining procedure was performed with two different Ig-isotype-matched nonsense antibodies. No positive staining pattern was seen on the negative controls [example shown in Fig. 1 (insert) ]. HLA-G1 is expressed on the surface of extravillous trophoblast cells and HLA-G5 produced in extravillous trophoblast cells (e.g. Hunt and Langat, 2009) , and therefore placental or endometrial (abortion) tissue slides were used as positive controls for the mAbs MEM-G/1, MEM-G/2, 5A6G7 and 2A12.
Results of the staining of first trimester placental (abortion) tissue from gestational week 6 by the four mAbs are shown in Fig. 1 . As expected, MEM-G/1, MEM-G/2 and 5A6G7 showed positive staining of extravillous trophoblast. MEM-G/1 and MEM-G/2 did not stain endometrial epithelial cells, as was the case for 5A6G7. The same staining patterns (of extravillous trophoblast) of these three mAbs have been reported before in the literature (Menier et al., 2003; LeMaoult et al., 2005; Helige et al., 2008) . For the MEM-G/1 and MEM-G/2 mAbs, no change in staining intensities and patterns were observed, when the 22-mer HLA-G intron 4 peptide was added in absorption control experiments, and this was expected (Fig. 5) . Furthermore, staining patterns of endometrial tissue are shown in Fig. 1 with the two intron-4-specific antibodies (2A12 and 5A6G7). Both the 2A12 and 5A6G7 mAbs stain endometrial epithelial cells, but only 5A6G7 stains extravillous trophoblast. The peptide absorbing experiments showed that the staining with the 5A6G7 mAb is absolutely blocked in all tissues tested (abortion tissue, testis, epididymis and prostate). In the testis and in the prostate tissues the staining by 2A12 is totally blocked; however, in the abortion tissue and in the epididymis sections, where the staining without peptide is very intense, some weak staining remains (Fig. 5) .
Positive reactions with the 2A12 and 5A6G7 mAbs, respectively, were observed in the testis (see Fig. 2 ). The results from the testicular tissue indicate that some of the Sertoli cells in the testis stain positive when HLA-G antibodies raised against the sHLA-G isoforms are tested. However, the testicular tissue showed no positive staining with the use of the two other HLA-G antibodies, MEM-G/1 and MEM-G/2. The same was observed with the paraffin-embedded epididymal tissue (Fig. 3) . Again, no positive reaction with MEM-G/1 and MEM-G/2 was observed, whereas 2A12 and 5A6G7 reacted with some of the cells in epididymis, especially the ductuli efferentis (the small seminal ducts leading from the testis to the head of the epididymis).
In tissue samples from the prostate gland, there was a positive reaction with 5A6G7 but no positive reactions with the three other antibodies (Fig. 4) . Finally, the seminal vesicle did not reveal any positive reactions with the four HLA-G-specific antibodies tested (results not shown).
In the four seminal samples that were embedded in a coagulation gel matrix and thereafter paraffin-embedded the staining of the panleukocyte marker CD45 clearly showed the presence of leukocytes. However, no staining was observed with the anti-HLA-G mAbs, MEM-G/1 and MEM-G/2, in any of the samples. For the 5A6G7 mAb against HLA-G5/-G6, the background versus specific signal had to be adjusted for optimal staining. With a dilution of 1:500, all cells in the seminal samples were negative. However, using this dilution, first trimester placental control tissue and epididymis were clearly positive, and testis was only very weak positive, indicating that sHLA-G expression in testis is less pronounced that in epididymis. The isotype controls were all negative. Representative examples of immunohistochemical staining of the seminal samples are shown in Fig. 6 .
Western blot analyses show the presence of sHLA-G in human seminal plasma
The presence of sHLA-G in seminal plasma was investigated by western blotting, using the antibody MEM-G/1. In order to confirm the results, the western blot analysis was performed on at least three separate occasions and semen samples were at least from four different male donors. The western blot results for MEM-G/1 showed the same binding patterns within the different blots, confirming that results were reproducible. Placental lysate was used as a positive control with a HLA-G protein band of 39 kDa (corresponding to the HLA-G1 isoform), in agreement with the literature.
Representative results obtained in the western blot experiments are shown in Fig. 6 . As seen in Fig. 7 (lanes 2-5) , HLA-G protein bands were observed in both the human seminal plasma samples and in human placenta lysate. Also, a weaker HLA-G protein band was observed in samples of human semen (not shown). Western blot with isolated sperm cells was also performed but all were negative (results not shown). In Fig. 7 , the human peripheral blood mononuclear cell (PBMC) lysate is positive (lane 7) demonstrating the presence of HLA-G in PBMCs. The negative controls, the boar seminal plasma and kidney lysate were negative in all blots made.
Protein bands with a molecular weight of 37 kDa with reactivity against MEM-G/1 were observed in all human seminal plasma samples. Thereby, the isotype of HLA-G present in seminal plasma is different from the isotype of 39 kDa observed in placenta (HLA-G1) (Kovats et al., 1990) . According to the molecular weight, the protein bands in seminal plasma (and one of the PBMC lysates), correspond to the soluble HLA-G5 isoform.
Soluble HLA-G is present in human seminal plasma in various concentrations
Levels of sHLA-G (sHLA-G1/HLA-G5) were measured in six different human seminal plasma samples with the use of a sHLA-G ELISA. Soluble HLA-G was detected in all seminal plasma samples (range 127 U/ml-.2000 U/ml; and 4.0 U/mg total protein to .45 U/mg total protein) (Fig. 8) . None of the negative controls showed any presence of sHLA-G. The results reveal that there is a high variability in seminal sHLA-G concentrations between male donors, also when these concentrations are standardized in relation to measurements of total protein in the samples.
For the four seminal samples analyzed in paraffin-embedded coagulation gels, the sHLA-G concentrations in the seminal plasma were in the range of 47 -1580 U/ml (not shown in Fig. 8 ).
Discussion
This study provides new evidence for the presence of HLA-G protein in seminal plasma and in tissue samples from the testis, epididymis and a weak occurrence of HLA-G in the prostate gland of the male reproductive system. Western blot was performed on different seminal plasma samples using MEM-G/1 as the primary anti-HLA-G mAb. In the western blot experiments (Fig. 7) , placental lysate was used as a positive control and showed a HLA-G protein band corresponding to the full length HLA-G1 (39 kDa) protein isoform. In the seminal plasma, protein bands were 35-37 kDa corresponding to the soluble HLA-G5 isoform. The soluble HLA-G6 isoform has a molecular weight of 28 kDa (Le Rond et al., 2004) and bands corresponding to this protein size were not detected. These results were reproducible in all four seminal plasma samples. As negative controls both boar seminal plasma and human kidney lysate were used. The boar seminal plasma was chosen as a control to obtain comparisons of two biologically alike sample materials (seminal plasma). No expression of HLA-G is normally found in kidneys, for which reason also the kidney lysate was used as a negative control. Both the boar seminal plasma and the kidney lysate were negative in all western blots indicating that no cross-reactions or other unspecific binding by MEM-G/1 took place. Samples of whole semen showed a weak HLA-G band. Isolated Figure 6 Immunohistochemical staining of cells in seminal samples. Cells were immobilized in a plasma-thrombin gel and paraffin-embedded. (A) 5A6G7 (dilution 1:500; magnification ×200). (B) As (A) (Magnification ×600). (C) MEM-G/1 (dilution 1:750; Magnification ×200) (D) As (C) (Magnification ×600). (E) Isotype control PPV-06 (dilution 1:500; Magnification ×200) (F) Anti-CD45 staining of leukocytes (dilution 1:50; Magnification ×600).
sperm cells did not show any reactivity with the specific anti-HLA-G mAb. Thus, the weak protein band observed in samples of semen at 35-37 kDa is probably due to HLA-G protein found in the seminal plasma (results not shown). The observation of an HLA-G protein band in all seminal plasma samples is a very interesting and original finding. The intensity of the HLA-G protein bands was different between the male donors. The variations in intensities of HLA-G bands can be due to different concentrations of sHLA-G in each seminal plasma sample, and this indicates that levels of sHLA-G protein in seminal plasma are varying between male donors. These observations are in accordance with the sHLA-G ELISA results that showed different concentrations of sHLA-G in seminal plasma from different male donors. When corrected for total protein content a substantial variation in sHLA-G content was still observed (Fig. 8) . In general, different levels of sHLA-G in blood samples have been detected from individual to individual in other studies. Such individual differences may at least partly be under genetic control (Hviid et al., 2003; Hviid et al., 2004; Chen et al., 2008) .
Human seminal plasma is produced by contributions from the seminal vesicle, prostate (prostate secretions) and bulbourethral glands. The origin of the HLA-G5 protein found in the seminal plasma in this study is not yet known. However, it is likely that HLA-G5 found in the seminal plasma originates from prostate gland secretions. This would be in agreement with previous observations made by Langat et al. (2006) that HLA-G5 protein is expressed and located in the prostate and prostate secretions. It cannot be excluded whether HLA-G5 can be expressed in other parts of the male reproductive system from the study by Langat and co-workers since only HLA-G expression in the prostate gland was addressed. To obtain more information about this, we examined a possible presence of HLA-G in different parts of the male reproductive system by immunohistochemistry.
Staining with HLA-G-specific antibodies was carried out in different tissues from the male reproductive system (Figs 1-5 ). Endometrial abortion tissue was used as a positive control. As expected, the MEM-G/1 and MEM-G/2 mAbs showed a strong reaction pattern with HLA-G protein in extravillous trophoblast cells (Fig. 1) . Furthermore, the 5A6G7 mAb, which is specific for the HLA-G5 and -G6 isoforms, clearly stained the extravillous trophoblast cells and also the endometrial epithelial cells (Fig. 1) ; the staining of the extravillous trophoblast is in accordance with that mentioned in the literature (LeMaoult et al., 2005) . However, LeMaoult et al. apparently did not observe a positive reaction in the endometrial epithelial cells with the 5A6G7 mAb. The 2A12 mAb that has also been raised against the HLA-G5 and -G6 isoforms positively stained the endometrial epithelial cells but not the trophoblast cells in the current study (Fig. 1) . The last finding was not expected and there is no obvious explanation for the differences in positive staining between the 5A6G7 and 2A12 mAbs. It would have been expected that the staining patterns by the 2A12 and 5A6G7 mAbs would have been the same. The discrepancy was observed in the abortion tissue, where 2A12 did not stain extravillous trophoblast. The two mAbs have been generated in the same way with the use of a 22-mer peptide corresponding to the C-terminal amino acid sequence of HLA-G5 and -G6 as immunogen. It has not been possible to find any reported use of the 2A12 mAb in the literature. Maybe the specificity could be slightly different between the two mAbs regarding the HLA-G5 and the HLA-G6 isoforms but this is pure speculation. When absorbing experiments with the 22-mer peptide corresponding to the C-terminal part of the HLA-G5 and -G6 was performed, the staining with the 2A12 mAb was not entirely blocked abortion tissue and epididymis, which stains very intensively with the 2A12 mAb, as it was with the 5A6G7 mAb. This could indicate a lesser degree of specificity for the 2A12 mAb but could also be a question of differences in sensitivity and concentrations in the absorbing experiments. We have not been able to find any descriptions of the staining patterns of the 2A12 mAb at the feto-maternal contact zone, or of other tissues, in the literature. In conclusion, the results obtained with the 2A12 mAb have to be evaluated very carefully, and in the current study it is chosen only to rely on the data obtained with the 5A6G7 mAb. The glandular epithelium of peritoneal endometriosis has been reported in one study to express HLA-G staining with the 4H84 mAb but not eutopic endometrium (samples obtained during the menstrual cycle) (Barrier et al., 2006a, b) . However, in a study by Kawashima et al. (2009) , the presence of HLA-G was observed using the MEM-G/1 mAb in eutopic endometrium but only in the menstrual phase. Furthermore, the presence of HLA-G has been reported in human decidual stromal cells (Blanco et al., 2008) .
A striking observation is that the 5A6G7 and 2A12 mAbs stain the endometrial epithelial cells, whereas the MEM-G/1 and MEM-G/2 mAbs do not. And in the male reproductive tissues in general, the same pattern is observed, with no positive staining with MEM-G/1 and MEM-G/2 at all. The results presented here taken together with the study by Langat et al. of prostate tissue clearly indicate that HLA-G5 is the isoform present in the male reproductive system (Langat et al., 2006) . This would further indicate that it is HLA-G5 and/or HLA-G6, which is located in the endometrial epithelial cells and that the MEM-G/1 and MEM-G/2 may fail to detect HLA-G5 when used in immunohistochemistry. The specificities of the MEM-G/1 and MEM-G/2 have been addressed in a publication by Menier et al. (2003) . It is shown that MEM-G/1 and MEM-G/2 can detect all denatured isoforms of HLA-G in western blotting. However, in the case of immunohistochemistry, it is only shown that MEM-G/1 stains extravillous trophoblast cells in paraffinembedded sections of human first-trimester placenta tissue. According to information from the manufacture (Exbio Praha) both MEM-G/1 and MEM-G/2 stain paraffin-embedded trophoblast cells but other tissues with weak HLA-G expression are stained only with MEM-G/2. Thus, tissues with low expression or occurrence of HLA -G could perhaps show reduced or lacking reactivity with the HLA-G heavy chain specific antibodies. Furthermore, differences in fixative might also influence the binding of the MEM-G/1 and MEM-G/2 mAbs, however, the same procedure has been used for all tissues and it performs very well in placenta sections.
Some of the interesting results obtained from the immunohistochemical staining were the detection of HLA-G in normal testis, epididymis, and the weak staining in prostate tissue. The positive reaction pattern in testis and epididymis were shown by the use of 5A6G7 and 2A12 mAbs specific for the HLA-G5 and HLA-G6 soluble isoforms. Only 5A6G7 showed a weak positive staining in prostate tissue, but not 2A12. This difference resembles the difference observed regarding the staining pattern of extravillous trophoblast and endometrial epithelial cells. Again, the specificity of the two mAbs, 2A12 and 5A6G7, may be different due to differences in the reactivity with HLA-G5 and -G6, respectively. However, this is very speculative, and to our knowledge, no systematic comparison of the staining patterns of these two mAbs has been published. As mentioned previously, it has been chosen only to rely on the results obtained with the well-described 5A6G7 mAb in this study. Previous studies by Langat et al. (2006) have shown the presence of HLA-G5 in prostate tissue; however, other HLA-G antibodies were used. In the current study, only a rather weak positive staining with the 5A6G7 mAb was observed supporting the presence of HLA-G5 and/or -G6 in prostate tissue. In the current study, only prostate tissue samples from cases with hyperplasia were investigated. Furthermore, the fact that completely different anti-HLA-G mAbs were used in the two studies could also explain differences in the staining patterns of the two sets of mAbs. Langat et al. (2006) concluded that HLA-G expression in adenocarcinomas from the prostate gland was either reduced or no longer detectable. Additional studies in normal prostate tissue are necessary for obtaining clear conclusions about the expression of HLA-G in prostate tissue. It cannot be fully excluded that the weak reaction with 5A6G7 could be due to non-specific reactivity against e.g. neurocrine cells. In summary, the study by Langat et al. (2006) of HLA-G expression in a normal human prostate and the results obtained in the current study strongly suggest that the prominent isoform of HLA-G expressed in the male reproductive system is the soluble HLA-G5 isoform.
To further validate, the presence of HLA-G in human seminal plasma, we also investigated the presence of sHLA-G molecules in seminal plasma samples from six male donors using a specific sHLA-G assay. All of theses samples were positive for sHLA-G in varying concentrations. This may also indicate that there might be individual differences in the expression level of HLA-G in the reproductive tissues from male to male influencing the immunohistochemical results. In further investigations, it would be interesting to analyze a large number of seminal plasma samples to further compare the different sHLA-G levels between individuals. Hypothetically, there could be a correlation between sHLA-G levels and the genotype of the male donor and it could be interesting to obtain more information about these aspects.
To clarify the possibility that leukocytes in the semen may be a source for sHLA-G, seminal samples from four donors were paraffin-embedded and sections stained with the anti-HLA-G mAbs and a leukocyte marker. The results were negative and indicate that leukocytes in the semen do not seem to contribute to sHLA-G in the seminal plasma (Fig. 6 ).
In accordance with results from the western blot, the immunohistochemistry, and the ELISA experiments, there are strong indications of HLA-G being expressed in parts of the male reproductive system. In the testis, HLA-G might have a functional role serving as an immunosuppressive factor, and thereby avoiding recognition of 'self' sperm cells, which are considered as autoantigens for the immune system. One of the functions of HLA-G might be the maintenance of the testes as an immune privileged site. In this regard, it is interesting that Sertoli cells seem to be immunoprotective and they seem to locate HLA-G (Mital et al., 2009) .
Several observations indicate that specific factors in seminal plasma can interact with cells and functional pathways in the female reproductive tract. It may lead to a range of cellular and molecular changes resembling an inflammatory response. The female genital tract is an immuno-competent mucosal site (reviewed in Robertson et al., 2003; Robertson, 2005) . Seminal plasma is not mandatory for initiation of viable pregnancies since these occurs using washed ejaculated sperm in artificial insemination. However, repeated exposure to semen in both animal models and in humans improve reproductive success (Robertson et al., 2003; Robertson, 2005) . In mice, it seems that uterine 'priming' with semen can promote implantation and fetal growth in subsequent pregnancies, even in a partner-specific manner (Beer et al., 1975) . In humans, live birth rates in couples undergoing IVF are significantly improved, when women are exposed to semen at the time of embryo transfer (Tremellen et al., 2000) . Local effects of natural insemination in peri-ovulatory women involve infiltration of macrophages, dendritic cells, granulocytes and lymphocytes into the cervical epithelium and stroma shortly following intercourse; however, this inflammatory response was not observed following condom-protected intercourse (Robertson, 2005) . These activated female immune cells may express cytokines and growth factors. Several factors in seminal plasma may be involved in the modulation of the inflammatory response in the cervix and the uterus. Two candidates for induction of tolerance to seminal antigens are transforming growth factor beta and prostaglandin E 2 , which can be detected in high concentrations within mammalian semen (Robertson et al., 2003; Robertson, 2005) . Furthermore, sHLA have been detected in semen, and one study has shown that repeated oral exposures to sperm seem to reduce the risk for developing preeclampsia (Koelman et al., 2000) . This would be in agreement with observations indicating a connection between HLA/HLA-G and preeclampsia (O'Brien et al., 2001; Hylenius et al., 2004; Yie et al., 2004; 2005; Moreau et al., 2008) . It can be hypothesized that the specific presence of HLA-G protein in seminal plasma and in semen as shown in the present study can be involved in the immunomodulation of the inflammatory response in the female reproductive tract. Interestingly, HLA-G5 seems to be involved in the induction of CD4+CD25highFOXP3+ regulatory T cells (Selmani et al., 2008) . The observations reported in the current study direct the attention to a possible function of paternal-derived HLA-G in the implantation process of the blastocyst and development of maternal tolerance. It is conceivable that HLA-G-in particular the soluble form HLA-G5-may have an important role in immuno-modulation (Hunt et al., 2005; Carosella et al., 2008) . One of the possible functions of HLA-G would be an interaction with leukocyte immunoglobulin-like receptor ((LILR) or immunoglobulin-like transcript), ILT2 and ILT4, leading to an inhibition of CD4T cell proliferation and alloreactivity, and the cytotoxic function of natural killer cells, in the female (e.g. Hunt et al., 2005) . Thus, repeated female exposure to semen and paternal factors therein-and the possible immuno-modulation generated in this way-may be important for the success of pregnancy.
In conclusion, the results of this study provide evidence that sHLA-G is present in varying amounts in human seminal plasma, and also that it is present in the testis and epididymis of the male reproductive system.
